Posted by Michael Wonder on 16 Dec 2025
Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in post-menopausal women
15 December 2025 - Sprout Pharmaceuticals today announced a monumental milestone for women's health: the US FDA has approved Addyi (flibanserin 100 mg) for the treatment of hypoactive sexual desire disorder in women <65 years.
This long awaited decision closes a gap in care for millions of post-menopausal women experiencing frustrating low sexual desire and marks a historic first approval for the FDA.
